Phio Pharmaceuticals(PHIO) - 2025 Q4 - Annual Results

Recent Corporate Updates Exhibit 99.1 Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance Sheet with $23.7 Million in Net Proceeds, Extending Cash Runway into the First Half of 2027 KING OF PRUSSIA, PA, March 5, 2026 (NEWSFILE) —Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-s ...